<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148062">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004587</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL014</org_study_id>
    <nct_id>NCT02004587</nct_id>
  </id_info>
  <brief_title>Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers</brief_title>
  <official_title>A Single-center, Open-label Trial, Investigating the Pharmacokinetics, Pharmacodynamics and the Safety Profile After a Single Oral Dose of Gemigliptin (Investigational Product) in Healthy Subjects and Subjects With Mild or Moderate Hepatic Impairment and After Multiple Oral Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an
      additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy
      White subjects will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Several time points until 72hr</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples will be prepared at planed points.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment group by Child-Pugh scores</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment group by Child-Pugh scores</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemigliptin dosing in Healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <description>Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.</description>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <other_name>Zemiglo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects who are able to understand and follow instructions during
             the study and available for study participation.

          -  Signed informed consent.

          -  White

        Exclusion Criteria:

          -  Unwilling or unable to give informed consent.

          -  As a result of the medical screening process, a study physician considers the subject
             unfit for the study.

          -  The subject has a history of drug or other allergy which contraindicated study
             participation.

          -  Female subjects who are pregnant or lactating.

          -  Any other condition (surgical or medical) or history of severe disease with sequelae
             which increases the risk to the subject or affected absorption, distribution,
             metabolism or excretion of the study drug or otherwise
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung Il Kim</last_name>
    <phone>82 2 6924 3112</phone>
    <email>sikim@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Zimmer</last_name>
      <phone>49 431 89998 04</phone>
      <email>larissa.zimmer@crs-group.de</email>
    </contact>
    <investigator>
      <last_name>Atef Halabi, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Gemigliptin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
